Cellenkos
Cellenkos is a clinical-stage biotechnology company focused on developing allogeneic, tissue-targeted, immune T-regulatory cell therapies to treat autoimmune diseases and inflammatory disorders. Founded in 2016, it leverages proprietary cord blood-derived Treg technology to create off-the-shelf cell-based products aimed at restoring immune balance and treating a wide spectrum of inflammatory conditions.
Industries
Nr. of Employees
small (1-50)
Cellenkos
5416 Chaucer Drive, Houston, TX 77005
Patents
Compositions comprising regulatory t cells and methods of making and using the same
US-12472182-B2
View Details
Compositions comprising regulatory t cells and methods of making and using the same
US-12472182-B2
View DetailsProducts
Allogeneic cord blood–derived regulatory T-cell therapy for bone marrow failure
Cryopreserved, off-the-shelf regulatory T-cell product derived from umbilical cord blood designed to home to bone marrow and suppress pathogenic cytotoxic T cells in bone marrow failure syndromes.
Cryopreserved cord blood–derived regulatory T-cell therapy for COVID-19 ARDS
Randomized, double-blind, placebo-controlled cryopreserved Treg infusion product evaluated for safety and early efficacy in COVID-19–induced ARDS.
CXCR4-enriched cord blood–derived regulatory T-cell therapy as add-on for myelofibrosis
A CXCR4-enriched, cryopreserved regulatory T-cell product developed for use as an add-on therapy to JAK inhibitor treatment in patients with myelofibrosis who have suboptimal response.
Neurotropic cord blood–derived regulatory T-cell therapy for neuroinflammatory disease (ALS)
Neurotropic, CNS-homing regulatory T-cell product in cryopreserved, off-the-shelf format developed for safety and preliminary efficacy evaluation in amyotrophic lateral sclerosis.
Allogeneic cord blood–derived regulatory T-cell therapy for bone marrow failure
Cryopreserved, off-the-shelf regulatory T-cell product derived from umbilical cord blood designed to home to bone marrow and suppress pathogenic cytotoxic T cells in bone marrow failure syndromes.
Cryopreserved cord blood–derived regulatory T-cell therapy for COVID-19 ARDS
Randomized, double-blind, placebo-controlled cryopreserved Treg infusion product evaluated for safety and early efficacy in COVID-19–induced ARDS.
CXCR4-enriched cord blood–derived regulatory T-cell therapy as add-on for myelofibrosis
A CXCR4-enriched, cryopreserved regulatory T-cell product developed for use as an add-on therapy to JAK inhibitor treatment in patients with myelofibrosis who have suboptimal response.
Neurotropic cord blood–derived regulatory T-cell therapy for neuroinflammatory disease (ALS)
Neurotropic, CNS-homing regulatory T-cell product in cryopreserved, off-the-shelf format developed for safety and preliminary efficacy evaluation in amyotrophic lateral sclerosis.
Services
On-site manufacturing, technology transfer, process development and scale-up for allogeneic cell therapy products with cryopreservation capabilities.
Design and conduct of early-phase clinical trials including Phase 1 safety runs, Phase 1b open-label studies and randomized, double-blind, placebo-controlled trials.
Sponsored research agreements and joint translational studies with academic medical centers to evaluate clinical applications of cell therapy products.
Provisioning and coordination of temperature-controlled, on-demand logistics solutions for cryopreserved cell therapy distribution to clinical sites and patients.
On-site manufacturing, technology transfer, process development and scale-up for allogeneic cell therapy products with cryopreservation capabilities.
Design and conduct of early-phase clinical trials including Phase 1 safety runs, Phase 1b open-label studies and randomized, double-blind, placebo-controlled trials.
Sponsored research agreements and joint translational studies with academic medical centers to evaluate clinical applications of cell therapy products.
Provisioning and coordination of temperature-controlled, on-demand logistics solutions for cryopreserved cell therapy distribution to clinical sites and patients.
Expertise Areas
- Allogeneic cell therapy development
- cGMP cell manufacturing and scale-up
- Clinical trial design and execution for cell therapies
- Regulatory submissions and IND-enabling activities
Key Technologies
- Cord blood–derived regulatory T cells
- Cell enrichment and activation platforms
- CXCR4-mediated homing enrichment
- Neurotropic/tissue-targeting cell modification
News & Updates
Cellenkos announced that its Phase 1b study data in myelofibrosis has been selected for oral presentation at the 66th Annual Meeting & Exposition of the American Society of Hematology (ASH), December 7-10, 2024.
Cellenkos announced a research collaboration with Mount Sinai to explore CK0804 for treatment of myelofibrosis.
Encouraging safety data allows Cellenkos to begin treating the second group of patients in its ALS trial with CK0803.
The VA Medical Center announced a new trial using CK0803, modified to target neuroinflammation in ALS.
The first patient was dosed in a Phase 1/1b study evaluating CK0803 for ALS.
Cellenkos announced that its Phase 1b study data in myelofibrosis has been selected for oral presentation at the 66th Annual Meeting & Exposition of the American Society of Hematology (ASH), December 7-10, 2024.
Cellenkos announced a research collaboration with Mount Sinai to explore CK0804 for treatment of myelofibrosis.
Encouraging safety data allows Cellenkos to begin treating the second group of patients in its ALS trial with CK0803.
The VA Medical Center announced a new trial using CK0803, modified to target neuroinflammation in ALS.
The first patient was dosed in a Phase 1/1b study evaluating CK0803 for ALS.